2. Signaling Pathways
  3. Immunology/Inflammation
  4. TREM receptor

TREM receptor

Triggering receptors expressed on myeloid cells

The Triggering Receptor Expressed on Myeloid cells (TREM) family consists of several receptors expressed on the surface of myeloid cells, among which TREM-1 and TREM-2 are the most extensively studied. TREM-1 acts as an amplifier of immune responses, significantly enhancing the responses of macrophages and neutrophils to bacteria and fungi, and promoting the release of inflammatory cytokines such as TNF-α and IL-1β, thus playing a crucial role in acute inflammation and infection responses. Modulating TREM-1 signaling can alleviate the severity of sepsis. TREM-2 helps regulate immune responses by promoting the anti-inflammatory and repair functions of macrophages, maintaining tissue stability, particularly in neural tissues, where the function of TREM-2 is closely associated with slowing the progression of neurodegenerative diseases like Alzheimer’s disease.
The Triggering Receptor Expressed on Myeloid cells interacts with its adaptor protein DAP12 to initiate signaling pathways, including those involving the tyrosine kinase Syk, which in turn activates a variety of downstream cellular responses, including the production of inflammatory cytokines, enhancement of cell survival signals, and reorganization of the cytoskeleton. The Triggering Receptor Expressed on Myeloid cells and their adaptor proteins are not only crucial for understanding immune regulation mechanisms but also provide new targets for the study of various diseases, including inflammatory and neurodegenerative diseases[1].

TREM receptor Isoform Specific Products:

TREM receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10227
    Bortezomib
    		Inhibitor 99.97%
    Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
    Bortezomib
  • HY-P10136
    IA9
    		Inhibitor
    IA9 (human TREM-2 182-190) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 can be used for neuroinflammation PET imaging. IA9 can be used for Rheumatoid arthritis (RA) and neuroinflammation research.
    IA9
  • HY-P3211A
    Nangibotide TFA
    		99.86%
    Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.
    Nangibotide TFA
  • HY-157122
    VJDT
    		Inhibitor 99.68%
    VJDT is a TREM1 inhibitor that can effectively block TREM1 signaling. VJDT inhibits tumor cell proliferation and migration and induces cell cycle arrest. VJDT has immunomodulatory and antitumor activities, and can be used for the research of tumors such as melanoma.
    VJDT
  • HY-P991220
    AL002
    		Agonist 98.01%
    AL002 is a humanized monoclonal IgG1 antibody and a blood-brain barrier-permeable TREM2 modulator. AL002 binds to TREM2 on the surface of microglia, promotes TREM2 clustering and the formation of the TREM2-DAP12 complex, activates the TREM2 signaling pathway and PI3K cascade, and induces TREM2 internalization and degradation. AL002 is applicable to research related to Alzheimer's disease.
    AL002
  • HY-182702
    As48
    		Agonist
    As48 is a selective TREM2 agonist with a KD value of 12.48 μM in TRIC binding assay. As48 binds near the TREM2 cleavage region, forms hydrogen bonds with Gly68, reduces conformational flexibility in regions 58-102, restricts protease accessibility to the cleavage site. As48 activates SYK phosphorylation, enhances microglial phagocytosis, and induces downstream calcium signaling in TREM2-expressing cells. As48 inhibits TREM2 ectodomain shedding without affecting ADAM10/17 protease activities. As48 can be used for the research of Alzheimer's disease.
    As48
  • HY-P992118
    Lifonebart
    		Inhibitor
    Lifonebart is a humanized monoclonal antibody targeting TREM2 (triggering receptor expressed on myeloid cells 2). The antibody isotype of Lifonebart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Lifonebart
  • HY-P990043
    Iluzanebart
    		Agonist 98.63%
    Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP).
    Iluzanebart
  • HY-P3211
    Nangibotide
    		98.53%
    Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.
    Nangibotide
  • HY-175510
    TREM2 agonist-5
    		Agonist 99.61%
    TREM2 agonist-5 is the microglial lipid-sensing receptor (TREM2) agonist with a Kd of 71.36 μM. TREM2 agonist-5 is a racemic structural analog of the TREM2 agonist VG-3927 and exhibits superior microglial phagocytosis and activates TREM2 signaling in HEK293-hTREM2/DAP12 cells. TREM2 agonist-5 displays a superior in vitro pharmacokinetic profile to VG-3927. TREM2 agonist-5 can used for the study of Alzheimer’s disease.
    TREM2 agonist-5
  • HY-P3211B
    Nangibotide scrambled peptide
    		Control 99.90%
    Nangibotide scrambled peptide (LR12-scr) is a scrambled control peptide composed of the same amino acids from LR12 (Nangibotide; HY-P3211) but in a random sequence (YQDVELCETGED).
    Nangibotide scrambled peptide
  • HY-P10136A
    IA9 TFA
    		Inhibitor 98.90%
    IA9 TFA (human TREM-2 182-190 TFA) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 TFA can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 TFA can be used for neuroinflammation PET imaging. IA9 TFA can be used for Rheumatoid arthritis (RA) and neuroinflammation research.
    IA9 TFA
  • HY-10227R
    Bortezomib (Standard)
    		Inhibitor
    Bortezomib (Standard) is the analytical standard of Bortezomib. This product is intended for research and analytical applications. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
    Bortezomib (Standard)
  • HY-174369
    TREM2 agonist-3
    		Antagonist 99.39%
    TREM2 agonist-3 (Compound 4i) is a TREM2 agonist with a KD value of 19.0 µM. The KD value of TREM2 agonist-3 for TREM1 is 39.8 µM. TREM2 agonist-3 induces an increase in phosphorylated SYK levels. TREM2 agonist-3 can be used in the research of neurodegenerative diseases and other diseases associated with TREM2 dysfunction.
    TREM2 agonist-3
  • HY-P990651
    PY314
    PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    PY314
  • HY-P991734
    VHB937
    		Agonist 99.9%
    VHB937 is a potent and selective TREM2 agonist, a human monoclonal antibody, with sub-nanomolar affinity. VHB937 enhances TREM2 surface expression and downstream signaling, such as Syk phosphorylation and calcium mobilization. VHB937 exhibits robust neuroprotective effects in vivo, significantly reducing pathology and pro-inflammatory markers across a broad range of animal models of neuroinflammation and neurodegeneration. VHB937 can be used for neurodegenerative diseases research.
    VHB937
  • HY-174378
    TREM2 agonist-4
    		Inhibitor 99.81%
    TREM2 agonist-4 (Compound 4a) is a TREM2 agonist with a Kd value of 45.9 μM. TREM2 agonist-4 can activate downstream signaling pathways of TREM2 and enhance the phagocytic function of microglia. TREM2 agonist-4 can be used in the research of neurodegenerative diseases such as Alzheimer's disease.
    TREM2 agonist-4
  • HY-178324
    T2M-010
    		Agonist
    T2M-010 is a potent, brain-penetrant TREM2 agonist (Kd = 0.83 μM). T2M-010 activates receptor-proximal signaling, inducing SYK phosphorylation in TREM2-expressing cells, and promotes microglial phagocytosis. T2M-010 can be used for the study of protective microglial responses relevant to Alzheimer’s disease (AD).
    T2M-010
  • HY-P991621
    EOS006215
    		Inhibitor 98.47%
    EOS006215 (EOS-215) is a humanized monoclonal antibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer.
    EOS006215
  • HY-P11077
    LR-17
    		Inhibitor
    LR-17 (TLT-1 (94-110)), a 17-aa peptide, is a TREM-1 inhibitor. LR-17 shows anti-inflammatory effects that can reduce the secretion of pro-inflammatory cytokines induced by Lipopolysaccharides (HY-D1056) (LPS). LR-17 can be used for the study of sepsis.
    LR-17
TREM receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.